ABOUT
CADT
Our programme is built on extensive international collaboration with leading scientists, academics, clinicians, industry experts and policy stakeholders. We are a Corporate Social Responsibility Company (CSR) that does not profit its directors or shareholders.
OUR
FOCUS
The world is currently in the grip of a global emergency due to the SARS-CoV-2 pandemic. The urgent need for accurate, rapid and affordable point-of-need diagnostics has never been clearer.
Global Oncology
Cancer is a leading cause of death globally, with 18 million new cancer cases and 9.5 million deaths recorded in 2018. Over half the world's cancer patients live in LMICs, unable to affordable novel diagnostics & effective therapeutics available in developed countries. For these patients, cancer is a neglected disease.
Whilst survival rates from colorectal, breast, prostate, cervical, and lung cancer are improving in high-income countries (HICs) due to a combination of early detection through faster, more accurate diagnostics and effective treatments, cancer death rates in LMICs are increasing. This is in part because many life-saving diagnostic tools and cancer treatments remain unaffordable for patients in LMICs.
Chronic infections such as Hepatitis B&C can also cause liver cancer, H.pylori gastric cancer, and Human Papilloma Virus (HPV) can cause cervical, anal, and some oral cancers. In 2018, 2.2 million cancers globally were attributable to infectious diseases.
WHAT MOTIVATES US
